hrvatski

Ispitivanje djelotvornosti, podnošljivosti i ekonomičnosti primjene cefixima u "switch" terapiji infekcija mokraćnog sustava i urosepse

In the period from January 1, 2005 and December 31, 2005 at the Institute for urinary tract infections of the University Hospital for Infectious Diseases &raquo ; Dr. Fran Mihaljevic&laquo ; , in Zagreb, we examined a total of 70 patients of both sexes, older than 18 years of age with diagnosed pyelonephritis and urosepsis, that received oral cefixime after parenteral empirical antimicrobial therapy. Disease etiology was determined in 62 patients. E. coli was isolated in 51 patients, P. mirabilis in 5, Kl. pneumoniae in 6. Empirical antimicrobial therapy was adequate in all patients. The criteria for switch to oral therapy were the following: afebrile patient for 12-24 hours, stabilization of general condition and leading clinical symptoms, tendency towards normalization in the number of leukocytes and findings of leukocyturia and bacteriuria, and no obstacles in the GI tract. The reasons for choosing cefixime for switch therapy were its efficacy, pharmacokinetic characteristics, once daily administration, reduced duration of treatment and possibility for quick discharge from hospital. Average duration of parenteral antimicrobial therapy, depending on administered drug, was 3 to 5 days, and of peroral therapy with cefixime 7 to 10 days. All patients were cured. There were no side effects to treatment. The cost of treatment per day, with switch from parenteral antimicrobial therapy to cefixim, decreased for up to 157 kunas.

Cefixime; Switch therapy; Urinary tract infections

nije evidentirano